Provided by Tiger Trade Technology Pte. Ltd.

MediciNova

1.60
-0.0200-1.23%
Post-market: 1.600.00000.00%17:14 EST
Volume:54.16K
Turnover:88.26K
Market Cap:78.63M
PE:-6.53
High:1.68
Open:1.65
Low:1.60
Close:1.62
52wk High:2.04
52wk Low:1.13
Shares:49.15M
Float Shares:42.08M
Volume Ratio:0.93
T/O Rate:0.13%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2449
EPS(LYR):-0.2253
ROE:-24.26%
ROA:-15.82%
PB:1.79
PE(LYR):-7.10

Loading ...

MediciNova Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Jan 30

MediciNova Reaches 100 Patients Enrolled in SEANOBI ALS Study for MN-166

Reuters
·
Jan 30

Medicinova Announces 100 Patients Enrolled in Seanobi Study Expanded-Access-Program (Eap) Evaluating Mn‑166 (Ibudilast) in ALS Patients

THOMSON REUTERS
·
Jan 30

MediciNova Inc - Top-Line Results Expected by End of 2026

THOMSON REUTERS
·
Jan 30

ATA Creativity Global Among 3 Promising Penny Stocks

Simply Wall St.
·
Jan 20

MediciNova Completes Enrollment in Three Clinical Trials and Expands ALS Access Program

Reuters
·
Jan 06

BRIEF-Medicinova Inc - On Dec 29, Entered $50 Million Equity Distribution Agreement With Lucid Capital Markets- SEC Filing

Reuters
·
Dec 30, 2025

MediciNova Inc - on Dec 29, Entered $50 Mln Equity Distribution Agreement With Lucid Capital Markets- SEC Filing

THOMSON REUTERS
·
Dec 30, 2025

MediciNova Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Dec 18, 2025

MediciNova Completes Enrollment for Phase 2 Trial of MN-166 in Metastatic Colorectal Cancer

Reuters
·
Dec 18, 2025

Medicinova Announces Completion of Patient Enrollment Evaluating Mn-166 (Ibudilast) in the Prevention of Chemotherapy-Induced Peripheral Neuropathy

THOMSON REUTERS
·
Dec 18, 2025

MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy

GlobeNewswire
·
Dec 18, 2025

MediciNova Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Dec 09, 2025

Medicinova Announces Update and Basic Characteristic Randomized Patients’ of Phase 2/3 Clinical Trial of Mn-166 (Ibudilast) in ALS (Combat-ALS Clinical Trial) Presented at the 36TH International Symposium on ALS/Mnd

THOMSON REUTERS
·
Dec 08, 2025

MediciNova Announces Update and Basic Characteristic Randomized Patients’ of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND

GlobeNewswire
·
Dec 08, 2025

MediciNova Inc - May Offer up to $300 Mln in Securities - SEC Filing

THOMSON REUTERS
·
Dec 06, 2025

MediciNova Reveals MN-001 Metabolite Boosts Cholesterol Efflux in Macrophages

Reuters
·
Dec 02, 2025

Message from the CEO to MediciNova Shareholders

GlobeNewswire
·
Dec 02, 2025

MediciNova names Dr. Christopher Breder as Clinical and Regulatory Advisor

TIPRANKS
·
Nov 18, 2025

Press Release: MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor

Dow Jones
·
Nov 18, 2025